ROXITHROMYCINE HUP

Roxithromycin is a semi-synthethic macrolide antibiotic that is structurally and pharmacologically similar to erythromycin, azithromycin, or clarithromycin.

It was shown to be more effective against certain Gram-negative bacteria, particularly Legionella pneumophila.

Roxithromycin exerts its antibacterial action by binding to the bacterial ribosome and interfering with bacterial protein synthesis.

It is marketed in

Australia as a treatment for respiratory tract, urinary and soft tissue infections.

Used to treat respiratory tract, urinary and soft tissue infections.

Roxithromycin has the following antibacterial spectrum in vitro: Streptococcus agalactiae, Streptococcus pneumoniae (Pneumococcus), Neisseria meningitides (Meningococcus), Listeria monocytogenes, Mycoplasma pneumoniae, Chlamydia trachomatis, Ureaplasma urealyticum, Legionella pneumophila, Helicobacter (Campylobacter), Gardnerella vaginalis, Bordetella pertussis, Moraxella catarrhalis ( Branhamella Catarrhalis ), and Haemophilus ducreyi.

Roxithromycin is highly concentrated in polymorphonuclear leukocytes and macrophages, achieving intracellular concentrations greater than those outside the cell.

Roxithromycin enhances the adhesive and chemotactic functions of these cells which in the presence of infection produce phagocytosis and bacterial lysis.

Roxithromycin also possesses intracellular bactericidal activity.

Very rapidly absorbed and diffused into most tissues and phagocytes.

Roxithromycin is only partially metabolised, more than half the parent compound being excreted unchanged.

Three metabolites have been identified in urine and faeces: the major metabolite is descladinose roxithromycin, with N-mono and N-di-demethyl roxithromycin as minor metabolites.

The respective percentage of roxithromycin and these three metabolites is similar in urine and faeces.

Hover over products below to view reaction partners Roxithromycin descladinose roxithromycin N-di-demethyl roxithromycin N-mono roxithromycin.

Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.

View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.

Roxithromycin primarily causes gastrointestinal adverse events, such as diarrhoea, nausea, abdominal pain and vomiting.

Less common adverse events include headaches, rashes, abnormal liver function values and alteration in senses of smell and taste.